VANQUISH 1

Active not recruitingPhase 3

VK2735 for Weight Management Phase 3

A Phase 3 Randomized, Double-Blind, Placebo-Controlled, 78-Week Efficacy and Safety Study of VK2735 Administered Subcutaneously for Weight Management in Participants Without Type 2 Diabetes Who Are Obese, or Overweight With at Least One Weight-related Comorbid Condition

Lead sponsor

Viking Therapeutics, Inc.

Asset

VK2735

Subcutaneous · GLP-1 / GIP dual

Listed sites

137

Recruiting sites

—

Enrollment

4,500

estimated

Study population

Obesity / overweight

Key I/E criterion

•BMI ≥30

Primary endpoint

•Body weight, % change

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07104500

Org study IDVK2735-301

Timeline

Milestones

Study start2025-06-23actual

Study first posted2025-08-05actual

Last update posted2025-11-24actual

Primary completion2027-07-01estimated

Study completion2027-08-01estimated

Assets

Investigational agents

VK2735

Study populations

Who this study enrolls

Obesity / overweight

Eligibility

Who can enroll

Minimum age18 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

1. Age ≥18 years of age at the time of signing the informed consent

2. Body mass index (BMI) ≥30 kg/m2 OR ≥27 kg/m2 with at least one weight-related co- morbid condition (treated or untreated)

–Weight-related co-morbid conditions include hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease

–Cardiovascular disease includes, for example, ischemic cardiovascular disease, New York Heart Association (NYHA) Functional Class I-III heart failure

–BMI calculated at the Screening visit will be used to determine eligibility

Exclusion criteria

1. History of or current clinically significant medical disorder that, in the opinion of the Investigator, does not support study participation

2. Self-reported body weight change of 5% or more within 3 months of screening

3. Have a prior or planned surgical treatment for obesity (excluding liposuction or abdominoplasty if performed >1 year prior to screening)

4. Have or plan to have endoscopic and/or device-based therapy for obesity or have had device removal within the last 6 months prior to screening (such as, mucosa ablation, gastric artery embolization, intragastric balloon, duodenal-jejunal endoluminal line)

5. Current or past diagnosis of diabetes mellitus (including type 1, type 2, except gestational diabetes)

6. Treatment with glucose-lowering agent(s) within 90 days before screening

7. Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2)

8. History of acute or chronic pancreatitis

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Weight & body composition

2 endpoints

Primary/protocol endpoint

Percentage change in body weight from baseline for participants receiving VK2735 after 78 weeks of treatment

Time frame:78 Weeks

Body weight, % change

percent change from baseline, improvement

Secondary/protocol endpoint

Percentage of participants who achieve ≥5%, ≥10%, ≥15% and ≥20% body weight reduction after 78 weeks of treatment

Time frame:78 Weeks

≥5% weight-loss responders

threshold achievement, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.